HBOT for Peripheral Arterial Disease (PAD) in Concord, CA

Peripheral arterial disease (PAD) is the progressive narrowing and obstruction of the arteries supplying the lower extremities, caused by atherosclerosis — the same process responsible for coronary artery disease and stroke. It affects an estimated 8 to 10 million Americans, with prevalence rising sharply after age 60 and in the presence of diabetes, smoking, hypertension, and hyperlipidemia. PAD is significantly underdiagnosed: only about half of affected patients have classic symptoms, while the others have atypical leg symptoms or none at all.

PAD is classified by severity. Mild to moderate PAD causes intermittent claudication — leg cramping during walking that resolves with rest. Severe PAD causes critical limb ischemia (CLI): rest pain, non-healing wounds, and gangrene. CLI represents the most severe end of the spectrum and is a major clinical emergency requiring urgent intervention; without effective treatment, one-quarter of CLI patients lose a limb within one year, and another quarter die from cardiovascular events.

The Contra Costa County and Bay Area population includes a significant population of older adults with cardiovascular risk factors including diabetes and hypertension who are at high risk for PAD. The overlap between PAD and diabetic foot disease — where arterial insufficiency and diabetic wound healing failure compound each other — is particularly common and particularly severe, and is a primary focus of NorCal Hyperbarics' wound care program.

The fundamental challenge of PAD-related wound care is that the wound bed — the tissue that must receive adequate oxygen to initiate and sustain healing — is served by the same obstructed arteries causing the problem. Revascularization (angioplasty, stenting, or bypass surgery) is the primary treatment, but many patients are not candidates due to anatomy, comorbidities, or failed prior attempts. In these patients, and as an adjunct to revascularization in others, HBOT provides oxygen via a completely different route: plasma diffusion.

At 2.0 to 2.5 atmospheres of 100% oxygen, the dissolved oxygen content of blood plasma rises to levels that can sustain tissue viability and wound healing even when red blood cell delivery is severely compromised. This plasma-dissolved oxygen diffuses into ischemic tissue independently of the arterial obstruction, supporting the fibroblast activation, collagen synthesis, and immune function that wound healing requires. HBOT also directly counteracts the pro-inflammatory, oxidative environment that characterizes PAD tissue — reducing macrophage-driven tissue damage and supporting the anti-inflammatory conditions that promote healing.

Critically, HBOT stimulates angiogenesis: the growth of new collateral blood vessels in the ischemic limb. Through VEGF upregulation and mobilization of endothelial progenitor cells from bone marrow, repeated HBOT sessions gradually build new capillary networks in oxygen-deprived tissue — creating a more favorable long-term vascular environment. This neovascularization effect persists beyond the treatment period, extending the benefit of HBOT beyond what direct oxygen delivery alone would produce. Dr. Toth coordinates HBOT for PAD patients alongside their vascular surgery and interventional cardiology teams, with protocols typically involving 30 to 40 sessions.